Hemab Therapeutics Holdings, Inc. Common Stock
NASDAQ:COAGBiotechnology
+$2.32 today
- Market cap
- $1.83B
- Beta
- 0.00
Volume 0.30M
Average 0.34M
COAG Deferred Revenue
Payments received for goods or services the company will deliver within the next year.
Hemab Therapeutics Holdings, Inc. Common StockNASDAQ: COAG
Deferred Revenue · Q2 FY2026 · quarter ended Jun 2026
Deferred revenue of $0 in Q2 FY2026
Q2 FY2026 deferred revenue was $0.
Context
- Deferred revenue amounted to 0.0% of total assets at the end of Q2 FY2026.
Sources:Balance SheetText generated from reported figures; not investment advice.
Deferred Revenue history
USD · from the balance sheet
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Deferred Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
Deferred Revenue vs competitors
How COAG compares with its peers on the latest reported figures
- COAG's Jun 2026 deferred revenue of $0 is the highest of the 5 companies compared; the peer median is $0.
- Deferred revenue amounts to 0.0% of total assets for COAG, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
COAGHemab Therapeutics Holdings, Inc. Common Stock | Jun 2026 | $0 | — | — | 0.0% |
IRONDisc Medicine, Inc. | Sep 2026 | $0 | — | — | 0.0% |
| Mar 2026 | $0 | — | +22.6% | 0.0% | |
DMRADamora Therapeutics, Inc. | Mar 2026 | $0 | — | — | 0.0% |
| Mar 2026 | $0 | -100.0% | — | 0.0% | |
| Peer median (excluding COAG) | $0 | -100.0% | +22.6% | 0.0% | |
Competitors are the stored peer set for COAG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Hemab Therapeutics Holdings, Inc. Common Stock
NASDAQ:COAG
Intrinsic Alpha fair value
Locked
Current Price
$39.15
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.